These results suggest that blocking the mechanisms responsible for cleavage of sumoylated GLT-1 in neurological diseases could prevent its internalization which would consequently elevate GLT-1 at the plasma membrane. This evidence concerns the gene SLC1A2 and nervous system disorder.